Skip to main content
Clinical Trials/NCT01041469
NCT01041469
Completed
Not Applicable

Pilot Study of Auto-immune Abnormalities Associated With Down Syndrome

Institut Jerome Lejeune2 sites in 1 country72 target enrollmentNovember 2009

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Down Syndrome With and Without Auto Immune Abnormalities
Sponsor
Institut Jerome Lejeune
Enrollment
72
Locations
2
Primary Endpoint
Auto-antibodies dosage
Status
Completed
Last Updated
14 years ago

Overview

Brief Summary

The purpose of the study is to identify biological data linked to auto immune abnormalities associated with Down Syndrome.

Registry
clinicaltrials.gov
Start Date
November 2009
End Date
December 2010
Last Updated
14 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Free and complete trisomy 21
  • aged between 8 and 36 years
  • biological or clinical signs of auto-immune disorder (group 1)
  • no sign of auto-immune disorder (group 2)

Exclusion Criteria

  • any antimitotic or immune depressing treatment during the last 6 months
  • Current infectious disease
  • Corticosteroid therapy in the last 3 weeks
  • pregnancy

Outcomes

Primary Outcomes

Auto-antibodies dosage

Time Frame: at enrolment

specific lymphocytes populations count

Time Frame: at enrolment

Study Sites (2)

Loading locations...

Similar Trials